The Report "Clinical Trial Imaging Market by Modality (CT, MRI, PET, Ultrasound, Echocardiography, X-Ray), Product & Services (Software), End User (Pharmaceutical Companies, Biotechnology Companies, CROs, Medical Device Manufacturers) - Global Forecast to 2021."
[123 Pages Report] The overall for clinical trial imaging market is projected to reach $1069.7 billion by 2021 from $773.4 billion in 2016, at a CAGR of 6.7% from 2016 to 2021.
[123 Pages Report] The overall for clinical trial imaging market is projected to reach $1069.7 billion by 2021 from $773.4 billion in 2016, at a CAGR of 6.7% from 2016 to 2021.
Increase in R&D spending by growing pharmaceutical and biotechnology industries is attributed to the growth of the market.
Download a FREE Pdf Broucher @: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=30446624
Based on the modality, the market is segmented into CT, MRI, PET, ultrasound, ECHO, x-ray, and other modalities (such as magnetic resonance elastography (MRE) and dual-energy X-ray absorptiometry (DXA)). The positron emission tomography (PET) segment is expected to grow at the highest CAGR during the forecast period. Growth in this segment can be attributed to the increasing usage of PET in clinical trials for screening various organs to obtain information about the function and metabolism.
On the basis of end user, the market is categorized into pharmaceutical companies, biotechnology companies, medical device manufacturers, contract research organizations, academic and government research institutes, and other end users (cosmetics and skin care companies). Medical device manufacturers segment is expected to grow at a highest CAGR during the forecast period. Increased R&D spending by medical device manufacturers and the growing medical devices market are factors contributing to the high growth of this end-user segment
Geographically, the market is segmented into North America, Europe, Asia, and the Rest of the World (RoW). Asia is expected to grow at the highest CAGR in the forecast period. The growth in the Asian clinical trial imaging market is driven by the growth in pharmaceutical & biotechnology industries and increase in R&D spending in the region.
The key players in the global market are BioClinica, Inc. (U.S.), Biomedical Systems (U.S.), Cardiovascular Imaging Technologies (U.S.), ICON Public Limited Company (Ireland), Intrinsic Imaging, LLC (U.S.), IXICO, PLC (U.K.), PAREXEL International Corporation (U.S.), Radiant Sage, LLC (U.S.), BioTelemetric, Inc. (U.S.), and WorldCare Clinical, LLC (U.S.). These players focus on inorganic and organic strategies such as greements, collaborations, and partnerships, expansions, acquisitions to sustain their growth in the global market.
Speak to our Analyst @: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=30446624
Download a FREE Pdf Broucher @: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=30446624
Based on the modality, the market is segmented into CT, MRI, PET, ultrasound, ECHO, x-ray, and other modalities (such as magnetic resonance elastography (MRE) and dual-energy X-ray absorptiometry (DXA)). The positron emission tomography (PET) segment is expected to grow at the highest CAGR during the forecast period. Growth in this segment can be attributed to the increasing usage of PET in clinical trials for screening various organs to obtain information about the function and metabolism.
On the basis of end user, the market is categorized into pharmaceutical companies, biotechnology companies, medical device manufacturers, contract research organizations, academic and government research institutes, and other end users (cosmetics and skin care companies). Medical device manufacturers segment is expected to grow at a highest CAGR during the forecast period. Increased R&D spending by medical device manufacturers and the growing medical devices market are factors contributing to the high growth of this end-user segment
Geographically, the market is segmented into North America, Europe, Asia, and the Rest of the World (RoW). Asia is expected to grow at the highest CAGR in the forecast period. The growth in the Asian clinical trial imaging market is driven by the growth in pharmaceutical & biotechnology industries and increase in R&D spending in the region.
The key players in the global market are BioClinica, Inc. (U.S.), Biomedical Systems (U.S.), Cardiovascular Imaging Technologies (U.S.), ICON Public Limited Company (Ireland), Intrinsic Imaging, LLC (U.S.), IXICO, PLC (U.K.), PAREXEL International Corporation (U.S.), Radiant Sage, LLC (U.S.), BioTelemetric, Inc. (U.S.), and WorldCare Clinical, LLC (U.S.). These players focus on inorganic and organic strategies such as greements, collaborations, and partnerships, expansions, acquisitions to sustain their growth in the global market.
Speak to our Analyst @: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=30446624
Comments
Post a Comment